Susquehanna International Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.05M Sell
18,513
-120,697
-87% -$7.04M ﹤0.01% 7776
2025
Q4
$8.27M Sell
139,210
-42,784
-24% -$2.33M ﹤0.01% 3305
2025
Q3
$9.86M Buy
181,994
+166,116
+1,046% +$9.5M ﹤0.01% 3058
2025
Q2
$873K Sell
15,878
-75,602
-83% -$4.45M ﹤0.01% 7780
2025
Q1
$6.47M Buy
91,480
+506
+0.6% +$34K ﹤0.01% 3184
2024
Q4
$5.98M Sell
90,974
-19,149
-17% -$1.28M ﹤0.01% 3337
2024
Q3
$7.74M Buy
110,123
+73,045
+197% +$6.11M ﹤0.01% 2962
2024
Q2
$3.05M Sell
37,078
-639,608
-95% -$53.2M ﹤0.01% 4278
2024
Q1
$59.1M Buy
676,686
+417,128
+161% +$37.3M 0.01% 923
2023
Q4
$25M Sell
259,558
-55,190
-18% -$4.88M ﹤0.01% 1582
2023
Q3
$27.8M Sell
314,748
-122,730
-28% -$10.9M 0.01% 1449
2023
Q2
$37.9M Buy
437,478
+89,563
+26% +$8.43M 0.01% 1183
2023
Q1
$33.8M Buy
347,915
+155,060
+80% +$16.1M 0.01% 1227
2022
Q4
$20M Sell
192,855
-80,282
-29% -$7.54M 0.01% 1523
2022
Q3
$23.2M Buy
273,137
+264,455
+3,046% +$23.5M 0.01% 1302
2022
Q2
$720K Sell
8,682
-87,429
-91% -$6.96M ﹤0.01% 7348
2022
Q1
$7.41M Sell
96,111
-24,194
-20% -$2.02M ﹤0.01% 2981
2021
Q4
$10.6M Sell
120,305
-102,090
-46% -$8.42M ﹤0.01% 2623
2021
Q3
$17.2M Buy
222,395
+96,560
+77% +$7.62M ﹤0.01% 2147
2021
Q2
$10.5M Sell
125,835
-296,140
-70% -$23.5M ﹤0.01% 2848
2021
Q1
$31.9M Buy
421,975
+57,791
+16% +$4.72M 0.01% 1436
2020
Q4
$31.9M Buy
364,184
+158,217
+77% +$12.5M 0.01% 1322
2020
Q3
$15.7M Buy
205,967
+45,096
+28% +$4.56M ﹤0.01% 1728
2020
Q2
$19.8M Sell
160,871
-51,873
-24% -$5.16M ﹤0.01% 1432
2020
Q1
$18M Sell
212,744
-383,070
-64% -$33M 0.01% 1250
2019
Q4
$50.4M Buy
595,814
+144,939
+32% +$10.9M 0.01% 799
2019
Q3
$30.4M Buy
450,875
+309,777
+220% +$23.9M 0.01% 1039
2019
Q2
$12.1M Buy
+141,098
New +$12.1M ﹤0.01% 1712
2018
Q3
Sell
-193,029
Closed -$19.3M 9225
2018
Q2
$18.2M Buy
193,029
+138,975
+257% +$12.2M 0.01% 1377
2018
Q1
$4.38M Sell
54,054
-148,539
-73% -$12.7M ﹤0.01% 2707
2017
Q4
$18.1M Buy
202,593
+186,042
+1,124% +$16.2M 0.01% 1327
2017
Q3
$1.54M Sell
16,551
-102,277
-86% -$9.04M ﹤0.01% 4403
2017
Q2
$10.8M Buy
118,828
+17,288
+17% +$1.57M ﹤0.01% 1636
2017
Q1
$8.91M Sell
101,540
-223,449
-69% -$19.9M ﹤0.01% 1730
2016
Q4
$26.9M Sell
324,989
-37,642
-10% -$3.24M 0.01% 853
2016
Q3
$33.6M Buy
362,631
+99,211
+38% +$9.34M 0.02% 705
2016
Q2
$20.5M Buy
263,420
+90,022
+52% +$7.65M 0.01% 959
2016
Q1
$14.3M Buy
173,398
+74,518
+75% +$6.06M 0.01% 1237
2015
Q4
$10.4M Buy
98,880
+51,538
+109% +$5.38M ﹤0.01% 1710
2015
Q3
$4.99M Sell
47,342
-177,574
-79% -$23.7M ﹤0.01% 2681
2015
Q2
$30.8M Buy
224,916
+67,316
+43% +$8.34M 0.01% 979
2015
Q1
$19.6M Buy
157,600
+116,980
+288% +$12.4M 0.01% 1248
2014
Q4
$3.67M Buy
40,620
+26,292
+184% +$2.19M ﹤0.01% 3372
2014
Q3
$1.03M Sell
14,328
-52,189
-78% -$3.43M ﹤0.01% 5853
2014
Q2
$4.14M Buy
66,517
+27,690
+71% +$1.67M ﹤0.01% 3379
2014
Q1
$2.65M Sell
38,827
-71,911
-65% -$5.3M ﹤0.01% 3837
2013
Q4
$7.78M Sell
110,738
-64,145
-37% -$4.36M ﹤0.01% 2362
2013
Q3
$12.6M Sell
174,883
-31,008
-15% -$2.06M 0.01% 1641
2013
Q2
$11.5M Buy
+205,891
New +$12.8M 0.01% 1634

Other funds holding BMRN

Susquehanna International Group's BMRN Position: Q1 2026 in Review

Susquehanna International Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 87% in Q1 2026, selling an estimated $7.04M and leaving 18,513 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #7776.

Susquehanna International Group first reported a position in BMRN in Q2 2013 and has held it in 49 quarters since. The position peaked at $59.1M in Q1 2024. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Susquehanna International Group held 18,513 shares of BioMarin Pharmaceuticals worth $1.05M as of Q1 2026.
  • Susquehanna International Group sold 120,697 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $7.04M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7776 holding.
  • Susquehanna International Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's BioMarin Pharmaceuticals position peaked at $59.1M in Q1 2024.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.